FDA spurns Min­er­va’s schiz­o­phre­nia drug in RTF, send­ing share price in­to tail­spin

The writ­ing was on the wall.

The FDA spelled out its qualms with Min­er­va Neu­ro­sciences’ schiz­o­phre­nia drug can­di­date rolu­peri­done in 2020. Nev­er­the­less, the biotech pushed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER